Given the link between depression, anxiety, and cannabis abuse, a serotonin receptor (rs6311) and transporter polymorphism (rs2020936) were examined as moderators of neural response as measured by functional magnetic resonance imaging following a psychosocial treatment for cannabis use disorders (CUDs). While the proposed hypotheses were unsupported, we found that the rs6311 C allele was significantly related to brain activation (medial frontal gyrus, precuneus), indicating the role of this serotonin receptor in adolescent treatment response.
Introduction
Adolescent cannabis use has been strongly correlated with a number of health risk behaviors (Chabrol et al., 2008; French and Dishion, 2003) , protracted use (Swift et al., 2008) , and poorer life outcomes during adulthood (Fergusson and Boden, 2008) . These trends are even more striking for justice-involved adolescents (Aarons et al., 2001) . Additionally, psychosocial treatments are the most frequently utilized approach for cannabis use disorders (CUDs; DHHS, 2009). However, only 26% of cannabis users successfully achieve abstinence following treatment (Dutra et al., 2008) . Notably, genetic factors may influence treatment outcomes (Anton et al., 2008; Bauer et al., 2007) . For example, the dopamine D4 receptor (DRD4) gene was found to moderate response to a motivational interviewing (MI) intervention targeting heavy drinking, with emerging adults with the protective allele evidencing better treatment response (Feldstein Ewing et al., 2009) . Most related research has focused on genes involved in craving, reward, and dependence (Filbey et al., 2010; Haughey et al., 2008; Schacht et al., 2009 ). Yet, the serotonergic system may be particularly salient to youths' vulnerability to CUDs and subsequent treatment response (Ló pez-Moreno et al., 2008; Sadeh et al., 2010; Otten and Engels, 2011) .
There are several reasons for this. First, serotonergic polymorphisms are involved in mood and anxiety symptoms. Risk alleles of single nucleotide polymorphisms (SNPs) on both the serotonin 2A receptor gene (5-HT-2A; rs6311 C allele; Dickel et al., 2007; Giegling et al., 2006; Unschuld et al., 2007) and the serotonin transporter gene (SLC6A4; rs2020936 A allele; Kramer et al., 2009; Wray et al., 2009 ) correspond with greater mood and anxiety disorders, aggression, and anger. Second, mood and anxiety symptoms are elevated among adolescent cannabis abusers (e.g., Diamond et al., 2006; Kaminer et al., 2008; Malmberg et al., 2010) , with some clinicians and researchers arguing that adolescents use cannabis to cope with negative affect (Fox et al., 2011) . Third, mood and anxiety symptoms have been found to influence treatment response (risk for relapse, e.g., Sinha and Li, 2007; Stein et al., 2011) .
Despite these connections, we could find no study explicitly evaluating the relationship between serotonin polymorphisms and treatment response. Thus, we sought to investigate the association between two types of serotonin polymorphisms (transporter gene; receptor gene) and blood oxygen level dependent (BOLD) response during an active ingredient of a 
